344 related articles for article (PubMed ID: 37509309)
21. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
23. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
De SK
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
[TBL] [Abstract][Full Text] [Related]
24. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.
Schultze MD; Reeves DJ
Ann Pharmacother; 2024 Jan; ():10600280231223737. PubMed ID: 38235739
[TBL] [Abstract][Full Text] [Related]
25. Current Approaches and Novel New Agents in the Treatment of Chronic Lymphocytic Leukemia.
Cheson BD; Sharman JP
JCO Oncol Pract; 2024 Jun; ():OP2300770. PubMed ID: 38848511
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA
J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
28. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract][Full Text] [Related]
29. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Wolska-Washer A; Robak P; Witkowska M; Robak T
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
[TBL] [Abstract][Full Text] [Related]
30. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Thompson PA; Tam CS
Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
[TBL] [Abstract][Full Text] [Related]
31. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Gordon MJ; Danilov AV
Ther Adv Hematol; 2021; 12():2040620721989588. PubMed ID: 33796237
[TBL] [Abstract][Full Text] [Related]
32. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
Eyre TA; Riches JC
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174062
[TBL] [Abstract][Full Text] [Related]
33. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
34. New Means and Challenges in the Targeting of BTK.
Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
Maruyama D; Wang C; Tanizawa Y; Cai Z; Huang Y; Tajimi M; Kusumoto S
J Clin Exp Hematop; 2023; 63(4):219-229. PubMed ID: 38148012
[TBL] [Abstract][Full Text] [Related]
36. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
37. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE; Wales TE; Jayne S; Britton RG; Fulton DB; Engen JR; Dyer MJS; Andreotti AH
bioRxiv; 2023 Dec; ():. PubMed ID: 38187560
[TBL] [Abstract][Full Text] [Related]
38. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
Zygmunciak P; Robak T; Puła B
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338868
[TBL] [Abstract][Full Text] [Related]
40. Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Simon F; Bohn JP
Curr Oncol Rep; 2023 Oct; 25(10):1181-1189. PubMed ID: 37682487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]